Developing efficient and safe cell-permeable reprogramming peptides for generation of iPS cells.

Information

  • Research Project
  • 8834649
  • ApplicationId
    8834649
  • Core Project Number
    R41GM113529
  • Full Project Number
    1R41GM113529-01
  • Serial Number
    113529
  • FOA Number
    PA-14-072
  • Sub Project Id
  • Project Start Date
    3/1/2015 - 9 years ago
  • Project End Date
    7/31/2016 - 8 years ago
  • Program Officer Name
    MAAS, STEFAN
  • Budget Start Date
    3/1/2015 - 9 years ago
  • Budget End Date
    7/31/2016 - 8 years ago
  • Fiscal Year
    2015
  • Support Year
    01
  • Suffix
  • Award Notice Date
    2/12/2015 - 9 years ago
Organizations

Developing efficient and safe cell-permeable reprogramming peptides for generation of iPS cells.

DESCRIPTION (provided by applicant): The groundbreaking discovery of induced pluripotent stem cells (iPSCs) has opened a new page for developing personalized cell-based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells. However, the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alteration and tumor formation. Generation of iPSCs by transient expression of pluripotent factors has decreased the safety concerns yet the reprogramming efficiency remains low. In this application, we propose to develop an improved, cell-permeable protein-based method to efficiently generate iPSCs. We have developed a rational approach to systematically engineer, produce, and validate robust, cell-penetrating reprogramming peptides that will overcome the key barriers to achieve high-efficiency and safe cellular reprogramming. The technology will enable us to efficiently produce patient-compatible iPSCs with the best safety profiles so as to derive other cell types safely for transplantation or for other types of clinical applications. Two Aims are proposed: Specific Aim 1 (Months 1-6): To construct a library of cell permeable human iPSC reprogramming proteins with modifications that would increase their reprogramming efficiency at Vivoscript Inc. Specific Aim 2 (Months 7-12): To evaluate the efficiency of these proteins in iPSC generation in Chen's lab at Sanford-Burnham Medical Research Institute.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R41
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    200082
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:200082\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    VIVOSCRIPT, INC.
  • Organization Department
  • Organization DUNS
    962814658
  • Organization City
    COSTA MESA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    926261431
  • Organization District
    UNITED STATES